Brokerages Set BioNTech SE (NASDAQ:BNTX) PT at $120.40

BioNTech SE (NASDAQ:BNTX) has been assigned a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $120.40.

A number of equities research analysts have recently commented on BNTX shares. BMO Capital Markets cut their price objective on BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a research report on Thursday, March 21st. Oppenheimer started coverage on BioNTech in a research report on Friday, January 5th. They set a “market perform” rating for the company. UBS Group cut their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research report on Wednesday, March 27th. The Goldman Sachs Group cut their price objective on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $107.00 price objective on shares of BioNTech in a research report on Wednesday.

BioNTech Stock Performance

BNTX opened at $86.17 on Tuesday. The company has a market capitalization of $20.49 billion, a price-to-earnings ratio of 20.92 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. BioNTech has a 1-year low of $85.21 and a 1-year high of $125.83. The business has a 50 day moving average price of $91.33 and a two-hundred day moving average price of $97.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. Research analysts predict that BioNTech will post -1.67 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares in the last quarter. CWM LLC boosted its holdings in BioNTech by 657.6% in the fourth quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after purchasing an additional 217 shares in the last quarter. State of Wyoming bought a new stake in BioNTech in the second quarter worth $26,000. Frazier Financial Advisors LLC bought a new stake in BioNTech in the fourth quarter worth $30,000. Finally, Covestor Ltd bought a new stake in BioNTech in the third quarter worth $32,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.